Verified Nov 2026
Other
·

Wilmington, Delaware
·
Since 1991
Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Employing approximately 2,500 people with estimated revenue of $5–10 billion, it develops small-molecule therapeutics for oncology, hematology, and inflammatory diseases. The company expanded its hematology portfolio through a 2026 acquisition and collaborates with partners including Novartis and Eli Lilly on approved products such as Jakafi for myelofibrosis.
Incyte at a glance
Revenue
$5-10B
Est. band
Employees
1,000-5,000
Founded
1991
Headquarters
Wilmington, Delaware
Certifications
ISO 14001 · ISO 45001 · ISO 50001
Import activity
4
Industries
Automotive
Electric Vehicles
Medical
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
4
Named foreign suppliers
3
Top origins
Germany · Belgium

Shared foreign counterparties do not establish that these companies buy from Incyte.
What this tells a buyer
Incyte received 161 documented shipments from three major suppliers: Konvekta in Switzerland (103 shipments), Siegfried in Belgium (53 shipments), and Becomix A Berents in Germany (5 shipments).
The company holds ISO 14001 (environmental management), ISO 45001 (occupational health and safety), and ISO 50001 (energy management) certifications.
In November 2026, Incyte entered a clinical collaboration with Natera on a Phase II interventional study in colorectal cancer, and expanded its molecular AI drug discovery partnership with Genesis.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
35 years in operation (founded 1991).
4 US import shipments on record.
Holds ISO 14001, ISO 45001, ISO 50001 certification(s) per public sources.
Overview
Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Employing approximately 2,500 people with estimated revenue of $5–10 billion, it develops small-molecule therapeutics for oncology, hematology, and inflammatory diseases. The company expanded its hematology portfolio through a 2026 acquisition and collaborates with partners including Novartis and Eli Lilly on approved products such as Jakafi for myelofibrosis.
At a glance
Attribute | Detail |
|---|---|
Founded | 1991 |
Headquarters | Wilmington, Delaware |
Employees | 1,000-5,000 |
Revenue | $5-10B (estimated) |
Certifications | ISO 14001 · ISO 45001 · ISO 50001 |
What Incyte makes
The company holds ISO 14001 (environmental management), ISO 45001 (occupational health and safety), and ISO 50001 (energy management) certifications.
Certifications
Incyte is associated with the following certifications in public sources. Confirm the certified scope for the specific plant producing your part:
ISO 14001 — dqsglobal.com
ISO 45001 — dqsglobal.com
ISO 50001 — dqsglobal.com
Trade and customs footprint
Incyte received 161 documented shipments from three major suppliers: Konvekta in Switzerland (103 shipments), Siegfried in Belgium (53 shipments), and Becomix A Berents in Germany (5 shipments). US customs bill-of-lading records list 4 inbound shipments across 3 foreign suppliers, with top origins including Germany · Belgium.
Latest developments
2026-11-10 — Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer (businesswire.com)
2026-06-08 — Incyte bolsters haematology portfolio in $2bn Vega buyout - Pharmaceutical Technology (pharmaceutical-technology.com)
2026-05-20 — Incyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery (businesswire.com)
2026-05-20 — Incyte pays Genesis $80M to expand AI-fueled drug discovery pact (fiercebiotech.com)
2026-02-11 — Incyte to sell Bracebridge buildings to BPG (delawarebusinesstimes.com)
2025-11-04 — Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors - Prelude Therapeutics (preludetx.com)
Company details
In November 2026, Incyte entered a clinical collaboration with Natera on a Phase II interventional study in colorectal cancer, and expanded its molecular AI drug discovery partnership with Genesis. Incyte was founded in 1991, has an estimated 1,000-5,000 employees, and is headquartered in Wilmington, Delaware. On the LightSource stability read it is rated "Established & active": 35 years in operation (founded 1991). 4 US import shipments on record. Holds ISO 14001, ISO 45001, ISO 50001 certification(s) per public sources.
Frequently asked questions
What does Incyte do?
Incyte Corporation is a global biopharmaceutical company headquartered in Wilmington, Delaware, founded in 1991. Employing approximately 2,500 people with estimated revenue of $5–10 billion, it develops small-molecule therapeutics for oncology, hematology, and inflammatory diseases. The company expanded its hematology portfolio through a 2026 acquisition and collaborates with partners including Novartis and Eli Lilly on approved products such as Jakafi for myelofibrosis.
Where is Incyte headquartered?
Incyte is headquartered in Wilmington, Delaware (1801 Augustine Cut Off, Wilmington, Delaware, 19803).
When was Incyte founded?
Incyte was founded in 1991.
How big is Incyte?
Incyte has an estimated 1,000-5,000 employees, with revenue in the $5-10B range (estimated).
What certifications does Incyte hold?
Incyte lists ISO 14001 · ISO 45001 · ISO 50001 on its website. Confirm the certified scope for the specific plant producing your part.
Does Incyte import from overseas suppliers?
US customs bill-of-lading records show 4 inbound shipments for Incyte, with top origins including Germany · Belgium.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Phone
'+1 302-498-6700
Certification
ISO 14001 · ISO 45001 · ISO 50001
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
